![Belatacept / Transplantation medicine / Renal function / Kidney transplantation / Co-stimulation / Chronic kidney disease / Dialysis / Transplant rejection / Medicine / Bristol-Myers Squibb / T cells Belatacept / Transplantation medicine / Renal function / Kidney transplantation / Co-stimulation / Chronic kidney disease / Dialysis / Transplant rejection / Medicine / Bristol-Myers Squibb / T cells](https://www.pdfsearch.io/img/d771e46bed958a6f2d6c16f4281f449f.jpg)
| Open Document File Size: 850,43 KBShare Result on Facebook
Company Bristol-Myers Squibb Company / Randomized Treatment Group / Bristol-Myers Squibb / / Event FDA Phase / / Facility Laboratory Findings / / IndustryTerm treatment for end-stage renal disease / / MedicalCondition onset diabetes / progressive renal dysfunction / Hypertension / Post-transplant Lymphoproliferative Disorder / First Serious Infection / interstitial fibrosis / Lymphoproliferative Disorder / Hypersensitivity / chronic allograft nephropathy / end-stage renal disease / Infections / Dyslipidemia / Malignant Neoplasms / Tuberculosis / / MedicalTreatment Renal transplantation / immunosuppression / immunosuppressive therapies / dialysis / renal transplant / / Organization FDA / Belatacept BMS-224818 IM103 Advisory Committee / / Position Briefing Document EXECUTIVE / / Product Cyclosporine / IM103008 / IM103 / IM103027 / Belatacept / BMS-224818 / / ProvinceOrState New Jersey / / RadioStation Core / / Technology Transplantation / dialysis / /
SocialTag |